Bivalirudin
Anticoagulation stewardship: Considerations for patients with cardiovascular disease
Anticoagulants are one of the most commonly prescribed medication classes, and the utilization of these agents is on the rise.
CAD does not increase short-term risk, major bleeding after TAVR
Patients with CAD were no more likely to experience major bleeding or adverse CV events after transcatheter aortic valve replacement compared with patients without CAD, according to a post hoc analysis of data from the BRAVO-3 study.
BRIGHT-4: Bivalirudin bests heparin in STEMI PCI with radial access
CHICAGO — In patients with STEMI undergoing primary PCI, mostly with radial artery access, anticoagulation with bivalirudin reduced death and major bleeding at 30 days compared with heparin, according to the results of the BRIGHT-4 trial.
VIDEO: Takeaways from AHA 2022 with B. Hadley Wilson, MD, FACC
CHICAGO — In this Healio exclusive, B. Hadley Wilson, MD, FACC, provides his perspective on several late-breaking clinical trials presented at the American Heart Association Scientific Sessions.
Part of the Healio Network
Direct Thrombin Inhibitors
There are a number of direct thrombin inhibitors. The most common are as follows:
Part of the Healio Network
Bivalirudin
Bivalirudin (Angiomax) is a direct thrombin inhibitor used as an anticoagulant to treat acute coronary syndromes. Administration is intravenous only and it has a short half-life of 25 minutes.